| Literature DB >> 35458222 |
Swarnim Gupta1, Mukhtiar Zaman2, Sadia Fatima3, Babar Shahzad3, Anna K M Brazier1, Victoria H Moran1, Martin R Broadley4,5, Munir H Zia6, Elizabeth H Bailey4, Lolita Wilson4, Iqbal M Khan7, Jonathan K Sinclair1, Nicola M Lowe1.
Abstract
Biofortification of wheat is potentially a sustainable strategy to improve zinc intake; however, evidence of its effectiveness is needed. A household-based, double-blind, cluster-randomized controlled trial (RCT) was conducted in rural Pakistan. The primary objective was to examine the effects of consuming zinc-biofortified wheat flour on the zinc status of adolescent girls aged 10-16 years (n = 517). Households received either zinc-biofortified flour or control flour for 25 weeks; blood samples and 24-h dietary recalls were collected for mineral status and zinc intake assessment. Plasma concentrations of zinc (PZC), selenium and copper were measured via inductively coupled plasma mass spectrometry and serum ferritin (SF), transferrin receptor, alpha 1-acid glycoprotein and C-reactive protein by immunoassay. Consumption of the zinc-biofortified flour resulted in a moderate increase in intakes of zinc (1.5 mg/day) and iron (1.2 mg/day). This had no significant effect on PZC (control 641.6 ± 95.3 µg/L vs. intervention 643.8 ± 106.2 µg/L; p = 0.455), however there was an overall reduction in the rate of storage iron deficiency (SF < 15 µg/L; control 11.8% vs. 1.0% intervention). Consumption of zinc-biofortified flour increased zinc intake (21%) but was not associated with an increase in PZC. Establishing a sensitive biomarker of zinc status is an ongoing priority.Entities:
Keywords: Pakistan; adolescent girls; biofortification; deficiency; iron status; minerals; plasma zinc concentration; wheat flour; zinc
Mesh:
Substances:
Year: 2022 PMID: 35458222 PMCID: PMC9026921 DOI: 10.3390/nu14081657
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Schematic overview of the study design. FFC, Fauji Fertilizer Company; HH, Households; COVID-19, Coronavirus disease.
Limits of detection (LOD) and quantification (LOQ) for four elements; all values are in µg/L.
| Element | Copper | Zinc | Selenium |
|---|---|---|---|
| Limit of detection (µg/L) | 0.074 | 0.941 | 0.010 |
| Limit of quantification (µg/L) | 0.248 | 3.136 | 0.033 |
Average recovery (%) for three elements compared to accredited values.
| CRM % Recovery | Copper | Zinc | Selenium |
|---|---|---|---|
| Seronorm L-1 | 86.5 | 89.4 | 102.2 |
| Seronorm L-2 | 86.8 | 86.0 | 103.4 |
Figure 2CONSORT flow diagram for the study. CONSORT, Consolidated Standards of Reporting Trials; HH, Households.
Baseline characteristics of the participating households (n = 486) and general characteristics of the recruited adolescent girls (n = 517) a by the study arms.
| Total | Arm 1 (Control in Phase 2) | Arm 2 (Intervention in Phase 2) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Mean (SD) | Median (Range) |
| Mean (SD) | Median (Range) |
| Mean (SD) | Median (Range) | |||||
|
| |||||||||||||
| Age | 517 | 12.1 (1.7) | 12.0 (8.6–15.3) | - | 260 | 12.2 (1.7) | 12.0 (9.3–15.3) | 257 | 12.1 (1.7) | 12.1 (8.6–15.3) | 0.954 | ||
| Attending school | 512 | 259 | 253 | ||||||||||
|
| 223 (43.6) | 104 (40.2) | 119 (47.0) | 0.116 | |||||||||
|
| 289 (56.4) | 155 (59.8) | 134 (53.0) | ||||||||||
| Ever attended school | 512 | 259 | 253 | ||||||||||
|
| 223 (43.6) | 104 (40.2) | 119 (47.0) | 0.106 | |||||||||
|
| 115 (22.5) | 54 (20.8) | 61 (24.1) | ||||||||||
|
| 155 (30.3) | 91 (35.1) | 64 (25.3) | ||||||||||
|
| 19 (3.7) | 10 (3.9) | 9 (3.6) | ||||||||||
| Education level c | 512 | 259 | 253 | ||||||||||
|
| 185 (36.1) | 80 (30.9) | 105 (41.5) | 0.034 | |||||||||
|
| 65 (12.7) | 39 (15.1) | 26 (10.3) | ||||||||||
|
| 12 (2.3) | 7 (2.7) | 5 (2.0) | ||||||||||
|
| 18 (3.5) | 6 (2.3) | 12 (4.7) | ||||||||||
|
| 58 (11.3) | 26 (10.0) | 32 (12.6) | ||||||||||
|
| 155 (30.3) | 91 (35.1) | 64 (25.3) | ||||||||||
|
| 19 (3.7) | 10 (3.9) | 9 (3.6) | ||||||||||
| Menarche attained | 506 | 256 | 250 | 0.580 | |||||||||
|
| 235 (46.4) | 122 (47.7) | 113 (45.2) | ||||||||||
|
| 271 (53.6) | 134 (52.3) | 137 (54.8) | ||||||||||
|
| |||||||||||||
|
| 486 | 250 | 236 | ||||||||||
| Family Size | 10.5 (4.8) | 9.0 (4.0–36.0) | 10.5 (4.5) | 9.0 (4.0–28.0 | 10.5 (5.0) | 9.0 (4.0–36.0) | 0.993 | ||||||
| No. of young children in HH | 2.1 (1.5) | 2.0 (1.0–10.0) | 2.1 (1.4) | 2.0 (1.0–8.0) | 2.2 (1.6) | 2.0 (1.0–10.0) | 0.735 | ||||||
| No. of older Children in HH | 1.5(1.1) | 1.0 (0.0–8.0) | 1.5 (1.1) | 1.0 (0.0–8.0 | 1.5 (1.1) | 1.0 (0.0–6.0) | 0.717 | ||||||
| No. of adolescents in HH | 3.0(1.6) | 3.0 (0.0–11.0) | 3.0 (1.6) | 3.0 (0.0–10.0) | 2.9 (1.7) | 3.0 (0.0–11.0) | 0.316 | ||||||
| No. of adolescent girls in HH | 1.7(1.1) | 1.0 (0.0–7.0) | 1.8 (1.1) | 2.0 (0.0–6.0) | 1.6 (1.2) | 1.0 (0.0–7.0) | 0.214 | ||||||
| No. of adult males in the HH | 1.9(1.4) | 1.0 (0.0–8.0) | 1.9 (1.4) | 1.0 (0.0–8.0) | 1.9 (1.4) | 1.0 (0.0–8.0) | 0.817 | ||||||
| No. of adult Females in the HH | 2.0(1.3) | 2.0 (0.0–7.0) | 2.0 (1.3) | 2.0 (0.0–6.0) | 2.1 (1.3) | 2.0 (1.0–7.0) | 0.429 | ||||||
|
| 483 | 249 | 234 | 0.769 | |||||||||
|
| 35(7.2) | 16 (6.4) | 19 (8.1) | ||||||||||
|
| 36(7.5) | 19 (7.6) | 17 (7.3) | ||||||||||
|
| 412(85.3) | 214 (85.9) | 198 (84.6) | ||||||||||
|
| |||||||||||||
| Source of Income e | 486 | 250 | 236 | ||||||||||
|
| 287 (59.1) | 150 (60.0) | 137 (58.1) | 0.662 | |||||||||
|
| 7 (1.4) | 4 (1.6) | 3 (1.3) | 0.761 | |||||||||
|
| 21 (4.3) | 15 (6.0) | 6 (2.5) | 0.061 | |||||||||
|
| 53 (10.9) | 23 (9.2) | 30 (12.7) | 0.214 | |||||||||
|
| 93 (19.1) | 49 (19.6) | 44 (18.6) | 0.789 | |||||||||
|
| 1 (0.2) | 1 (0.4) | 0 (0.0) | 0.331 | |||||||||
|
| 1 (0.2) | 1 (0.4) | 0 (0.0) | 0.331 | |||||||||
|
| 1 (0.2) | 1 (0.4) | 0 (0.0) | 0.331 | |||||||||
|
| 4 (0.8) | 2 (0.8) | 2 (0.8) | 0.954 | |||||||||
|
| 23(4.7) | 10 (4.0) | 13 (5.5) | 0.434 | |||||||||
| Monthly Income | 485 | 250 | 235 | 0.423 | |||||||||
|
| 297 (61.2) | 147 (58.8) | 150 (63.8) | ||||||||||
|
| 173 (35.7) | 96 (38.4) | 77 (32.8) | ||||||||||
|
| 15 (3.1) | 7 (2.8) | 8 (3.4) | ||||||||||
| Monthly Expenditure | 483 | 248 | 235 | 0.477 | |||||||||
|
| 228 (47.2) | 112 (45.2) | 116 (49.4) | ||||||||||
|
| 239 (49.5) | 129 (52.0) | 110 (46.8) | ||||||||||
|
| 16 (3.3) | 7 (2.8) | 9 (3.8) | ||||||||||
| Possession of Assets e | 454 | 238 | 216 | ||||||||||
|
| 130 (28.6) | 66 (27.7) | 64 (29.6) | 0.655 | |||||||||
|
| 33 (7.3) | 15 (6.3) | 18 (8.3) | 0.405 | |||||||||
|
| 400 (88.1) | 209 (87.8) | 191 (88.4) | 0.841 | |||||||||
|
| 39 (8.6) | 19 (8.0) | 20 (9.3) | 0.628 | |||||||||
|
| 88 (19.4) | 45 (18.9) | 43 (19.9) | 0.788 | |||||||||
|
| 5 (1.1) | 1(0.4) | 4 (1.9) | 0.144 | |||||||||
| House Ownership | 486 | 250 | 236 | 0.740 | |||||||||
|
| 395 (81.3) | 200 (80.0) | 195 (82.6) | ||||||||||
|
| 72 (14.8) | 40 (16.0) | 32 (13.6) | ||||||||||
|
| 19 (3.9) | 10 (4.0) | 9 (3.8) | ||||||||||
| Structure of House | 485 | 249 | 236 | 0.765 | |||||||||
|
| 227 (46.8) | 113 (45.4) | 114 (48.3) | ||||||||||
|
| 143 (29.5) | 74 (29.7) | 69 (29.2) | ||||||||||
|
| 115 (23.7) | 62 (24.9) | 53 (22.5) | ||||||||||
| Number of Rooms house | 481 | 3.1 (1.8) | 3.0 (1.0–11.0) | 248 | 3.2 (1.9) | 3.0 (1.0–11.0) | 233 | 3.0 (1.7) | 3.0 (1.0–11.0) | 0.605 | |||
| Toilet present in House | 486 | 250 | 236 | 0.845 | |||||||||
|
| 444 (91.4) | 229 (91.6) | 215 (91.1) | ||||||||||
|
| 42 (8.6) | 21 (8.4) | 21 (8.9) | ||||||||||
| No. of toilets in House | 466 | 1.0 (0.6) | 1.0 (0.0–4.0) | 242 | 1.1 (0.6) | 1.0 (0.0–4.0) | 224 | 1.0 (0.5) | 1.0 (0.0–4.0) | 0.614 | |||
|
| |||||||||||||
| Meal preparation facility in House | 486 | 250 | 236 | 0.781 | |||||||||
|
| 9 (1.9) | 6 (2.4) | 3 (1.3) | ||||||||||
|
| 313 (64.4) | 163 (65.2) | 150 (63.6) | ||||||||||
|
| 63 (13.0) | 31 (12.4) | 32 (13.6) | ||||||||||
|
| 8 (1.6) | 5 (2.0) | 3 (1.3) | ||||||||||
|
| 93 (19.1) | 45 (18.0) | 48 (20.3) | ||||||||||
| Source of drinking water | 484 | 249 | 235 | 0.009 | |||||||||
|
| 438 (90.5) | 234 (94.0) | 204 (86.8) | ||||||||||
|
| 13 (2.7) | 2 (0.8) | 11 (4.7) | ||||||||||
|
| 5 (1.0) | 4 (1.6) | 1 (0.4) | ||||||||||
|
| 14 (2.9) | 5 (2.0) | 9 (3.8) | ||||||||||
|
| 14 (2.9) | 4 (1.6) | 10 (4.3) | ||||||||||
|
| |||||||||||||
| Engagement of HH with the vaccination program | 466 | 243 | 223 | 0.006 | |||||||||
|
| 447 (95.9) | 239 (98.4) | 208 (93.3) | ||||||||||
|
| 19 (4.1) | 4 (1.6) | 15 (6.7) | ||||||||||
| Diarrheal incidence among children (1–5 years of age) within HH in past month | 486 | 250 | 236 | 0.974 | |||||||||
|
| 196 (40.3) | 101 (40.4) | 95 (40.3) | ||||||||||
|
| 290 (59.7) | 149 (59.6) | 141(59.7) | ||||||||||
| RTI incidence among children 1–5 years within HH in past month | 486 | 250 | 236 | 0.039 | |||||||||
|
| 198 (40.7) | 113 (45.2) | 85 (36.0) | ||||||||||
|
| 288 (59.3) | 137 (54.8) | 151 (64.0) | ||||||||||
| RTI incidence among adolescent girls (10–16 years of age) within HH in past month | 486 | 250 | 236 | 0.005 | |||||||||
|
| 107 (22.0) | 68 (27.2) | 39 (16.5) | ||||||||||
|
| 379 (78.0) | 182 (72.8) | 197 (83.5) | ||||||||||
|
| |||||||||||||
| Type of flour used | 486 | 250 | 236 | 0.062 | |||||||||
|
| 93 (19.1) | 47 (18.8) | 46 (19.5) | ||||||||||
|
| 101(20.8) | 59 (23.6) | 42 (17.8) | ||||||||||
|
| 282 (58.0) | 143 (57.2) | 139 (58.9) | ||||||||||
|
| 9 (1.9) | 1 (0.4) | 8 (3.4) | ||||||||||
|
| 1(0.2) | 0 (0.0) | 1 (0.4) | ||||||||||
| Source of flour procurement | 486 | 250 | 236 | 0.109 | |||||||||
|
| 445 (91.6) | 224 (89.6) | 221 (93.6) | ||||||||||
|
| 41 (8.4) | 26 (10.4) | 15 (6.4) | ||||||||||
| Monthly flour consumption (Kgs) | 485 | 107.4 (45.1) | 100.0 (10.0–300.0) | 249 | 107.8 (44.2) | 100.0 (40.0–300.0 | 236 | 107.1 (46.1) | 100.0 (10.0–300.0) | 0.882 | |||
| Monthly consumption of other staple h (Kgs) | 443 | 6.7 (8.2) | 4.5 (0.0–120.0) | 230 | 7.2 (10.1) | 4.3 (0.0–120.0) | 213 | 6.2 (5.6) | 5.0 (0.0–40.0) | 0.280 | |||
| Purchase practice for flour (mode of payment) | 479 | 248 | 231 | 0.678 | |||||||||
|
| 237 (49.5) | 126 (50.8) | 111 (48.1) | ||||||||||
|
| 168 (35.1) | 87 (35.1) | 81 (35.1) | ||||||||||
|
| 74 (15.4) | 35 (14.1) | 39 (16.9) | ||||||||||
| Preferred term of supply in the first six months i | 481 | 247 | 234 | 0.354 | |||||||||
|
| 313 (65.1) | 168 (68.0) | 145 (62.0) | ||||||||||
|
| 94 (19.5) | 43 (17.4) | 51 (21.8) | ||||||||||
|
| 74 (15.4) | 36 (14.6) | 38 (16.2) | ||||||||||
All data presented in the table were collected at the time of enrolment. HH, household; UPS, device for uninterruptible power supply. a One or more participants were included from each household. b p-values obtained using linear mixed models adjusted for cluster effect to test differences between the groups for continuous variable and categorical variables by Pearson’s chi-squared test. Significance was set at p < 0.05. c Primary schooling is defined as grade 1–5 (grade 1 to ≤5), middle as grade 6–8 (grade 6 to ≤8), high as grade 9–10 grade (grade 9 to ≤10) irrespective of the girl is attending school at present or had dropped out. d Population sub-groups defined as young children: ≤5 years of age; older children: ≥5 to <10 years of age; adolescents: ≥10 to ≤19 years of age; Adults: >19 years of age. e Descriptive indicates number (%) of only those who responded ‘yes’ against a category of source of income/possession of a particular asset. f Family member(s) working outside of the country as main source of HH income. g A mode of transportation that are generally battery-driven tricycles and used for carrying goods or people. h Other cereals include rice and maize, collectively. i For the duration of phase 1 (stabilization phase).
Baseline values for haematological outcome measures of the enrolled adolescent girls.
|
| Total |
| Control |
| Intervention | ||
|---|---|---|---|---|---|---|---|
| Plasma zinc concentrations, PZC (µg/L) | 420 | 624.7 ± 88.2 | 221 | 628.2 ± 93.6 | 199 | 620.8 ± 81.7 | 0.893 |
| Zinc deficiency (PZC < 650 µg/L for age < 10 years or 660 µg/L for ≥10 years) | 420 | 289 (68.8) | 221 | 146 (66.1) | 199 | 143 (71.9) | 0.2 |
| Serum iron (µg/L) | 420 | 894.9 (659.1–1110.1) | 221 | 888.5 (672.7–1130.4) | 199 | 910.1 (651.9–1100.8) | 0.824 |
| Serum iron <598 µg/L | 420 | 81(19.3) | 221 | 43 (19.5) | 199 | 38 (19.1) | 0.925 |
| Serum ferritin, SF (ng/mL) $ | 417 | 21.1 (11.3–33.7) | 221 | 22.5 (12.2–35.6) | 196 | 20.1 (11.2–33.5) | 0.552 |
| Storage iron deficiency (SF < 15 ng/mL) | 417 | 147 (35.3) | 221 | 68 (30.8) | 196 | 79 (40.3) | 0.042 |
| Serum transferrin receptor, STFR (mg/L) | 418 | 3.4 (2.9–4.0) | 220 | 3.4 (2.8–4.0) | 198 | 3.4 (3.0–4.1) | 0.267 |
| Functional iron deficiency (SFTR > 4.59 mg/L) | 418 | 56 (13.4) | 220 | 29 (13.2) | 198 | 27 (13.6) | 0.892 |
| Iron deficiency (SF < 15 ng/mL or SFTR > 4.59 mg/L) | 417 | 167 (40.0) | 221 | 80 (36.2) | 196 | 87 (44.4) | 0.089 |
| Haemoglobin, Hb (g/dL) | 419 | 12.8 ± 1.2 | 12.9 ± 1.3 | 200 | 12.8 ± 1.1 | 0.715 | |
| Anaemia (Hb < 11.5 g/dL for < 12 years or < 12.0 g/dL for ≥12 years) | 419 | 69.0 (16.5) | 219 | 39 (17.8) | 200 | 30 (15.0) | 0.439 |
| Iron Deficiency Anaemia (SF < 15 ng/mL or SFTR > 4.59 mg/L and Hb < 11.5 g/dL for <12 years or <12.0 g/dL for 12 years) | 420 | 39 (9.3) | 221 | 22 (10.0) | 199 | 17 (8.5) | 0.619 |
| Anaemia Grade: | 419 | 219 | 200 | 0.651 | |||
| Mild (Hb = 11.0–11.4 g/dL for <12 years or 11.0–11.9 g/dL for ≥12 years) | 43 (10.3) | 23 (10.5) | 20 (10.0) | ||||
| Moderate (Hb = 8.0–10.9 g/dL) | 25 (6.0) | 15 (6.8) | 10 (5.0) | ||||
| Severe (Hb < 8.0 g/dL) | 1 (0.2) | 1(0.5) | 0 (0.0) | ||||
| Non- anaemic (Hb ≥ 11.5 g/dL for <12 years or ≥12.0 g/dL for ≥12 years) | 350 (83.5) | 180 (82.2) | 170 (85.0) | ||||
| Red blood cell count, RBC count (106/µL) | 420 | 4.6 ± 0.5 | 220 | 4.6 ± 0.5 | 200 | 4.6 ± 0.5 | 0.564 |
| RBC count < 3.84 × 106/µL | 420 | 16 (3.8%) | 220 | 7 (3.2%) | 200 | 9 (4.5%) | 0.481 |
| Mean corpuscular volume, MCV (fL) | 417 | 82.1 ± 7.0 | 217 | 82.0 ± 7.5 | 200 | 82.3 ± 6.4 | 0.714 |
| MCV < 74.7 fL | 417 | 41 (9.8%) | 217 | 23 (10.6%) | 200 | 18 (9.0%) | 0.584 |
| Haematocrit, HCT (%) | 420 | 37.5 ± 3.0 | 220 | 37.5 ± 3.1 | 200 | 37.5 ± 2.8 | 0.857 |
| HCT < 33.5% | 420 | 33 (7.9%) | 220 | 21 (9.5%) | 200 | 12(6.0%) | 0.177 |
| Mean corpuscular haemoglobin concentration, MCHC (g/dL) | 420 | 34.2 ± 1.3 | 220 | 34.2 ± 1.3) | 200 | 34.1 ± 1.3 | 0.842 |
| MCHC < 32.3 g/dL | 420 | 34 (8.1) | 220 | 18 (8.2) | 200 | 16 (8.0) | 0.946 |
| C-reactive protein, CRP (mg/dL) | 414 | 0.03 (0.02–0.07) | 219 | 0.03 (0.02–0.06) | 195 | 0.04 (0.02–0.08) | 0.902 |
| CRP >0.5 mg/dL | 414 | 2 (0.5) | 219 | 1 (0.5) | 195 | 1(0.5) | 0.934 |
| Alpha 1-acid glycoprotein, AGP (mg/dL) | 420 | 61.2 (45.5–74.5) | 221 | 58.8 (43.3–71.6) | 199 | 63.7 (48.2–79.6) | 0.052 |
| AGP > 100 mg/dL | 420 | 14.0 (3.3) | 221 | 4 (1.8) | 199 | 10 (5.0) | 0.067 |
| Plasma selenium (µg/L) | 418 | 102.8 ± 13.6 | 220 | 101.6 ± 12.4) | 198 | 104.2 ± 14.7 | 0.020 |
| Selenium deficiency (Plasma selenium < 41.8 μg/L) | 418 | 0 (0.0) | 220 | 0 (0.0) | 198 | 0(0.0) | - |
| Plasma copper (µg/L) | 420 | 930.4 ± 171.3 | 221 | 914.4 ± 183.0 | 199 | 948.1 ± 155.8 | 0.117 |
| Copper deficiency (Plasma copper < 750 μg/L for < 10.3 years; <640 μg/L for 10.3–12.5 y; <570 μg/L for >12.5 y) | 420 | 8 (1.9) | 221 | 7 (3.2) | 199 | 1 (0.5) | 0.046 |
| Copper:Zinc ratio | 420 | 1.5 (1.3–1.7) | 221 | 1.4 (1.2–1.7) | 199 | 1.5 (1.3–1.7) | 0.214 |
Data presented as Mean ± SD, Median (IQR), or n (%). All the haematological parameters were assessed at the beginning of the intervention phase (T3) of the study. * p-values obtained using linear mixed models adjusted for cluster effect to test differences between the groups for continuous variable and categorical variables by Pearson’s chi-squared test. Significance was set at p < 0.05. $ Serum ferritin adjusted for inflammation [25].
Comparative summary of the mineral content for two varieties of wheat flour.
| Galaxy | Zincol-2016 | β (CI) * | t |
| |
|---|---|---|---|---|---|
| Zinc (mg/kg) | 17.0 ± 2.6 | 20.7 ± 5.6 | 3.696 (2.258, 5.134) | 5.083 | <0.001 |
| (16.4–17.6) | (19.2–22.1) | ||||
| Iron (mg/kg) | 23.8 ± 4.7 | 26.8 ± 5.6 | 3.044 (1.293, 4.794) | 3.439 | 0.001 |
| (22.6–24.9) | (25.4–28.2) | ||||
| Copper | 2.6 ± 0.9 | 2.9 ± 1.2 | 0.344 (−0.019, 0.707) | 1.875 | 0.063 |
| (2.4–2.8) | (2.6–3.2) | ||||
| Selenium | 45.0 ± 13.2 | 51.3 ± 14.2 | 6.235 (1.610, 10.860) | 2.666 | 0.009 |
| (42.0–48.1) | (47.7–54.9) | ||||
| Calcium | 326.4 ± 25.3 | 340.3 ± 22.9 | 13.924 (5.702, 22.146) | 3.349 | 0.001 |
| (320.4–332.3) | (334.4–346.1) | ||||
| Phosphorus | 2.2 ± 0.2 | 2.4 ± 0.2 | |||
| (2.2–2.3) | (2.3–2.4) | 0.169 (0.093, 0.245) | 4.405 | <0.001 |
Data outside of parenthesis indicates Mean ± SD. CI (95%) are presented within the parenthesis. * Values represent beta coefficient and 95% CI from linear regression models. p was set at < 0.05.
Consumption of wheat bread and corresponding zinc, iron and phytate intakes (n = 412).
| Wheat Bread Consumption (g/Day) | Zinc | Iron | Phytate | |||||
|---|---|---|---|---|---|---|---|---|
| FCD * | Galaxy | Zincol-2016 | FCD* | Galaxy | Zincol-2016 | FCD * | ||
| Mean ± SD | 541 ± 134 | 7.8 ± 2.0 | 6.9 ± 1.7 | 8.4 ± 2.1 | 12.3 ± 3.1 | 9.6 ± 2.4 | 10.9 ± 2.7 | 1584 ± 397.1 |
| Median (Range) | 525 | 7.7 | 6.7 | 8.1 | 12.0 | 9.4 | 10.6 | 1548 |
Analysis included only those participants for whom at least two 24 h dietary recalls were available. Galaxy was the standard variety used as control; Biofortified variety Zincol-2016 was the intervention. * FCD, Food Composition Database. Mineral and phytate intakes were calculated based on the Indian food composition database [32].
Figure 3Plasma zinc concentration for the participants over time.
Zinc deficiency prevalence for all participants (n = 420) and plasma zinc concentration of subgroup with zinc deficiency at baseline (n = 146) over time by study arms.
| Time Points |
| Control |
| Intervention | X2 | β (CI) * | t |
| |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Baseline | 221 | 146 (66.1) | 199 | 143(71.9) | 1.639 | 0.200 | |||
| Midpoint | 213 | 159 (74.6) | 192 | 141(73.4) | 0.077 | 0.781 | |||
| Endline | 214 | 129 (60.3) | 188 | 121 (64.4) | 0.709 | 0.400 | |||
|
| |||||||||
| Baseline | 146 | 581.8 ± 54.5 | 143 | 581.9 ± 51.2 | |||||
| Midpoint | 140 | 591.9 ± 69.1 | 136 | 584.2 ± 77.2 | −2.563(−24.156, 19.030) | −0.242 | 0.810 | ||
| Endline | 142 | 613.3 ± 79.8 | 134 | 619.3 ± 103.5 | 11.085 (−19.865, 42.035) | 0.733 | 0.470 |
* All the participants included. ** Only those with zinc plasma levels below the age-specific IZiNCG cut-offs at baseline included [5]. * Values represent beta coefficient and 95% CI from linear regression models. p-values obtained using linear mixed models adjusted for cluster effect and baseline values to test differences between the groups for continuous variables. Categorical variables tested by Pearson’s chi-squared test. Significance was set at p < 0.05.
Biomarkers of Iron status by study arm at baseline, midpoint and endline.
| Outcomes | Time Points |
| Control |
| Intervention | β (95%CI) * | X2 | t |
|
|---|---|---|---|---|---|---|---|---|---|
| Serum iron (µg/L) | Baseline | 221 | 888.5 (672.7–1130.4) | 199 | 910.1 (651.9–1100.8) | ||||
| Midpoint | 213 | 877.2 (632.3–1104.3) | 192 | 894.5 (676.0–1127.2) | 33.539 (−43.606, 110.684) | 0.879 | 0.385 | ||
| Endline | 214 | 856.7 (610.9–1077.5) | 188 | 828.1 (552.9–1060.6) | −28.302 (91.397, 34.793) | −0.921 | 0.365 | ||
| Serum iron < 598 µg/L | Baseline | 221 | 43 (19.5) | 199 | 38 (19.1) | 0.009 | 0.925 | ||
| Midpoint | 213 | 45 (21.1) | 192 | 35 (18.2) | 0.535 | 0.465 | |||
| Endline | 214 | 49 (22.9) | 188 | 54 (28.7) | 1.783 | 0.182 | |||
| Serum Ferritin, SF (ng/mL) $ | Baseline | 221 | 22.5 (12.2–35.6) | 196 | 20.1 (11.2–33.5) | ||||
| Midpoint | 212 | 26.2 (15.2–40.5) | 194 | 23.1 (14.2–33.8) | −3.525 (−8.254, 1.203) | −1.515 | 0.139 | ||
| Endline | 213 | 17.4 (9.2–31.2) | 188 | 17.8 (7.3–29.5) | −3.549 (−8.622, 1.523) | −1.418 | 0.165 | ||
| Storage iron deficiency (SF <15 ng/mL) | Baseline | 221 | 68 (30.8) | 196 | 79 (40.3) | 4.139 | 0.042 | ||
| Midpoint | 212 | 49 (23.1) | 194 | 50 (25.8) | 0.389 | 0.533 | |||
| Endline | 213 | 88 (41.3) | 188 | 80 (42.6) | 0.063 | 0.802 | |||
| Serum Transferrin Receptor, STFR (mg/L) | Baseline | 220 | 3.4 (2.8–4.0) | 198 | 3.4 (3.0–4.1) | ||||
| Midpoint | 212 | 3.3 (2.9–3.9) | 191 | 3.4 (3.0–4.0) | −0.005 (−0.241, 0.232) | −0.040 | 0.968 | ||
| Endline | 210 | 3.2 (2.8–3.8) | 187 | 3.3 (2.7–4.1) | 0.112 (−0.178, 0.403) | 0.779 | 0.440 | ||
| Functional iron deficiency (SFTR > 4.59 mg/L) | Baseline | 220 | 29 (13.2) | 198 | 27 (13.6) | 0.019 | 0.892 | ||
| Midpoint | 212 | 26 (12.3) | 191 | 19 (9.9) | 0.544 | 0.461 | |||
| Endline | 210 | 26 (12.4) | 187 | 32 (17.1) | 1.775 | 0.183 | |||
| Iron deficiency (SF < 15 ng/mL or SFTR > 4.59 mg/L) | Baseline | 221 | 80 (36.2) | 196 | 87 (44.4) | 2.901 | 0.089 | ||
| Midpoint | 209 | 60 (28.7) | 192 | 57 (29.7) | 0.046 | 0.829 | |||
| Endline | 213 | 90 (42.3) | 188 | 88 (46.8) | 0.839 | 0.360 | |||
| Iron Deficiency anaemia (SF <15 ng/mL or SFTR > 4.59 mg/L and Hb < 11.5 g/dL for <12 years or <12.0 g/dL for | Baseline | 221 | 22 (10.0) | 199 | 17 (8.5) | 0.248 | 0.619 | ||
| Midpoint | 213 | 16 (7.5) | 195 | 13 (13.9) | 0.110 | 0.740 | |||
| Endline | 213 | 23 (10.8) | 188 | 25 (13.3) | 0.592 | 0.442 |
Data presented as Mean ± SD, Median (IQR), or n (%). $ Ferritin adjusted for inflammation [25]. * Values represent beta coefficient and 95% CI from linear regression models. p-values obtained using linear mixed models adjusted for cluster effect and baseline values to test differences between the groups for continuous variables. Categorical variables tested by Pearson’s chi-squared test. Significance was set at p < 0.05.
Plasma copper and selenium concentration, and inflammation markers by study arm at baseline, midpoint and endline.
| Outcomes | Time Points |
| Control |
| Intervention | β (95%CI) * | X2 | t | |
|---|---|---|---|---|---|---|---|---|---|
| Plasma copper (µg/L) | Baseline | 221 | 914.4 ± 183.0 | 199 | 948.1 ± 155.8 | ||||
| Midpoint | 213 | 926.3 ± 139.3 | 191 | 961.3 ± 154.5 | 16.882 (−7.130, 40.894) | 1.447 | 0.160 | ||
| Endline | 214 | 871.0 ± 147.3 | 187 | 907.9 ± 155.9 | 18.562 (−10.056, 47.180) | 1.326 | 0.195 | ||
| Copper deficiency (plasma copper < 750 μg/L for <10.3 years; <640 μg/L for 10.3–12.5 years; <570 μg/L for >12.5 years) | Baseline | 221 | 7 (3.2) | 199 | 1 (0.5) | 3.980 | 0.046 | ||
| Midpoint | 213 | 2 (0.9) | 191 | 1 (0.5) | 0.236 | 0.627 | |||
| Endline | 214 | 10 (4.7) | 187 | 2 (1.1) | 4.464 | 0.035 | |||
| Plasma selenium (µg/L) | Baseline | 220 | 101.6 ± 12.4 | 198 | 104.2 ± 14.7 | ||||
| Midpoint | 213 | 98.5 ± 13.1 | 192 | 101.4 ± 12.7 | 0.960 (−2.637, 4.556) | 0.536 | 0.595 | ||
| Endline | 213 | 95.7 ± 12.1 | 188 | 96.0 ± 13.4 | −0.270 (−3.483, 2.943) | −0.170 | 0.866 | ||
| Copper:zinc ratio | Baseline | 221 | 1.4 (1.2–1.7) | 199 | 1.5 (1.3–1.7) | ||||
| Midpoint | 213 | 1.5 (1.3–1.7) | 191 | 1.6 (1.4–1.8) | 0.032 (−0.026, 0.090) | 1.116 | 0.273 | ||
| Endline | 214 | 1.4 (1.2–1.6) | 187 | 1.4 (1.3–1.6) | 0.024 (−0.032, 0.081) | 0.876 | 0.388 | ||
| C-reactive protein, CRP (mg/dL) | Baseline | 219 | 0.03 (0.02–0.06) | 195 | 0.04 (0.02–0.08) | ||||
| Midpoint | 213 | 0.030 (0.02–0.05) | 194 | 0.03 (0.02–0.06) | 0.005 (−0.014, 0.023) | 0.535 | 0.597 | ||
| Endline | 212 | 0.03 (0.02–0.05) | 186 | 0.03 (0.02–0.07) | 0.005 (−0.011, 0.021) | 0.603 | 0.552 | ||
| CRP > 0.5 mg/dL | Baseline | 219 | 1 (0.5) | 195 | 1 (0.5) | 0.007 | 0.934 | ||
| Midpoint | 213 | 0 (0.0) | 194 | 2 (1.0) | 2.207 | 0.137 | |||
| Endline | 212 | 1 (0.5) | 186 | 1 (0.5) | 0.009 | 0.926 | |||
| Alpha 1-acid glycoprotein, AGP (mg/dL) | Baseline | 221 | 58.8 (43.3–71.6) | 199 | 63.7 (48.2–79.6) | ||||
| Midpoint | 214 | 66.5 (55.6–80.5) | 194 | 66.4 (56.3–79.7) | 0.552 (−4.001, 5.106) | 0.246 | 0.807 | ||
| Endline | 214 | 69.5 (57.5–83.0) | 188 | 63.7 (52.8–76.8) | −4.548 (−8.921, −0.175) | −2.148 | 0.042 | ||
| AGP > 100 mg/dL | Baseline | 221 | 4 (1.8) | 199 | 10 (5.0) | 3.359 | 0.067 | ||
| Midpoint | 214 | 12 (5.6) | 194 | 17 (8.8) | 1.534 | 0.215 | |||
| Endline | 214 | 14 (6.5) | 188 | 5 (2.7) | 3.350 | 0.067 |
No deficiency of selenium observed (Plasma selenium < 41.8 μg/L). Data presented as Mean ± SD, Median (IQR), or n (%). * Values represent beta coefficient and 95% CI from linear regression models. p-values obtained using linear mixed models adjusted for cluster effect and baseline values to test differences between the groups for continuous variables. Categorical variables tested by Pearson’s chi-squared test. Significance was set at p < 0.05.
Spearman correlation coefficient between plasma copper and selenium concentrations and inflammatory markers.
| Copper | Selenium | C-Reactive Protein | Alpha-1-Acid Glycoprotein | Copper:Zinc Ratio | ||
|---|---|---|---|---|---|---|
| Copper | rs | 1.000 | 0.166 ** | 0.216 ** | 0.252 ** | 0.744 ** |
|
| 2169 | 2160 | 2123 | 2163 | 2168 | |
| Selenium | rs | 0.166 ** | 1.000 | 0.062 ** | −0.001 | −0.005 |
|
| 2160 | 2165 | 2119 | 2158 | 2159 | |
| C-Reactive Protein | rs | 0.216 ** | 0.062 ** | 1.000 | 0.456 ** | 0.189 ** |
|
| 2123 | 2119 | 2154 | 2150 | 2122 | |
| Alpha-1-Acid Glycoprotein | rs | 0.252 ** | −0.001 | 0.456 ** | 1.000 | 0.222 ** |
|
| 2163 | 2158 | 2150 | 2193 | 2162 | |
| Copper:Zinc ratio | rs | −0.573 ** | −0.086 ** | 0.222 ** | 0.090 ** | 1.000 |
|
| 2168 | 2153 | 2162 | 2152 | 2168 | |
** p-value < 0.01. rs, Spearman correlation coefficient.